HRP20160387T1 - Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor - Google Patents

Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor Download PDF

Info

Publication number
HRP20160387T1
HRP20160387T1 HRP20160387TT HRP20160387T HRP20160387T1 HR P20160387 T1 HRP20160387 T1 HR P20160387T1 HR P20160387T T HRP20160387T T HR P20160387TT HR P20160387 T HRP20160387 T HR P20160387T HR P20160387 T1 HRP20160387 T1 HR P20160387T1
Authority
HR
Croatia
Prior art keywords
degrees
alk
salt
compound
positive
Prior art date
Application number
HRP20160387TT
Other languages
English (en)
Croatian (hr)
Inventor
Martin J. Jacobs
Gregory R. Ott
Laurent Courvoisier
Shawn P. Allwein
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892060&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20160387(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of HRP20160387T1 publication Critical patent/HRP20160387T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
HRP20160387TT 2012-03-06 2013-03-06 Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor HRP20160387T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
EP13710258.8A EP2822939B1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
PCT/US2013/029304 WO2013134353A1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Publications (1)

Publication Number Publication Date
HRP20160387T1 true HRP20160387T1 (hr) 2016-05-20

Family

ID=47892060

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160387TT HRP20160387T1 (hr) 2012-03-06 2013-03-06 Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor

Country Status (28)

Country Link
US (5) US9132128B2 (enExample)
EP (2) EP3056494B1 (enExample)
JP (2) JP6016953B2 (enExample)
KR (1) KR102068374B1 (enExample)
CN (2) CN104159894B (enExample)
AU (1) AU2013229995B2 (enExample)
CA (1) CA2865420C (enExample)
CL (1) CL2014002353A1 (enExample)
CY (1) CY1117565T1 (enExample)
DK (1) DK2822939T3 (enExample)
EA (2) EA025859B1 (enExample)
ES (2) ES2681487T3 (enExample)
HR (1) HRP20160387T1 (enExample)
HU (1) HUE027976T2 (enExample)
IL (2) IL234239A (enExample)
ME (1) ME02460B (enExample)
MX (2) MX372740B (enExample)
MY (1) MY177290A (enExample)
NZ (1) NZ630251A (enExample)
PH (1) PH12014501979A1 (enExample)
PL (1) PL2822939T3 (enExample)
RS (1) RS54689B1 (enExample)
SG (2) SG10201507865QA (enExample)
SI (1) SI2822939T1 (enExample)
SM (1) SMT201600134B (enExample)
UA (1) UA115052C2 (enExample)
WO (1) WO2013134353A1 (enExample)
ZA (1) ZA201406147B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2822939T3 (pl) * 2012-03-06 2016-08-31 Cephalon Inc Skondensowane bicykliczne pochodne 2,4-diaminopirymidyny jako podwójne inhibitory ALK i FAK
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
HK1244789B (en) * 2014-12-23 2019-12-06 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
BR112021002145A2 (pt) 2018-08-07 2021-12-14 In3Bio Ltd Métodos e composições para inibição da via egf/egfr em combinação com inibidores da quinase de linfoma anaplásico
WO2024178339A2 (en) * 2023-02-23 2024-08-29 The Regents Of The University Of Michigan Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
BR122019017579B8 (pt) 2003-08-15 2021-07-27 Novartis Ag 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica
CN1918158B (zh) * 2004-02-14 2011-03-02 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CA2559866A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
ES2622493T3 (es) * 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta de JAK
EP2222647B1 (en) 2006-10-23 2015-08-05 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
KR101364277B1 (ko) * 2006-12-08 2014-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
DK2146779T3 (en) * 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
PL2975024T3 (pl) * 2009-06-10 2018-09-28 Chugai Seiyaku Kabushiki Kaisha Związki tetracykliczne
PL2822939T3 (pl) * 2012-03-06 2016-08-31 Cephalon Inc Skondensowane bicykliczne pochodne 2,4-diaminopirymidyny jako podwójne inhibitory ALK i FAK
KR101446742B1 (ko) * 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
HK1244789B (en) * 2014-12-23 2019-12-06 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives

Also Published As

Publication number Publication date
WO2013134353A8 (en) 2014-06-19
EA201691574A1 (ru) 2017-03-31
CN106166155A (zh) 2016-11-30
EP2822939B1 (en) 2016-02-17
PH12014501979B1 (en) 2014-11-24
AU2013229995A1 (en) 2014-09-25
ES2570976T3 (es) 2016-05-23
JP2017039741A (ja) 2017-02-23
KR20140138247A (ko) 2014-12-03
PL2822939T3 (pl) 2016-08-31
US9623026B2 (en) 2017-04-18
IL252364B (en) 2018-03-29
AU2013229995B2 (en) 2017-04-13
US9339502B2 (en) 2016-05-17
IL234239A (en) 2017-06-29
EA201491641A1 (ru) 2015-04-30
MY177290A (en) 2020-09-10
CA2865420C (en) 2020-06-02
US20150374693A1 (en) 2015-12-31
SMT201600134B (it) 2016-07-01
US10632119B2 (en) 2020-04-28
HK1226300A1 (zh) 2017-09-29
HK1205119A1 (zh) 2015-12-11
EA033124B1 (ru) 2019-08-30
EP3056494A1 (en) 2016-08-17
CL2014002353A1 (es) 2015-01-09
DK2822939T3 (en) 2016-03-14
US20160243119A1 (en) 2016-08-25
HUE027976T2 (en) 2016-11-28
WO2013134353A1 (en) 2013-09-12
EP2822939A1 (en) 2015-01-14
JP6016953B2 (ja) 2016-10-26
US10111872B2 (en) 2018-10-30
CN104159894B (zh) 2016-09-07
SG11201405371PA (en) 2014-09-26
US20190328735A1 (en) 2019-10-31
MX372740B (es) 2020-05-04
US9132128B2 (en) 2015-09-15
ES2681487T3 (es) 2018-09-13
ME02460B (me) 2017-02-20
US20170173017A1 (en) 2017-06-22
MX2014010613A (es) 2014-09-18
EA025859B1 (ru) 2017-02-28
SI2822939T1 (sl) 2016-04-29
KR102068374B1 (ko) 2020-01-20
JP2015509540A (ja) 2015-03-30
UA115052C2 (uk) 2017-09-11
PH12014501979A1 (en) 2014-11-24
CN104159894A (zh) 2014-11-19
CY1117565T1 (el) 2017-04-26
US20150011561A1 (en) 2015-01-08
CN106166155B (zh) 2019-01-18
MX347772B (es) 2017-05-12
IL252364A0 (en) 2017-07-31
NZ630251A (en) 2016-02-26
EP3056494B1 (en) 2018-05-02
ZA201406147B (en) 2015-12-23
RS54689B1 (sr) 2016-08-31
CA2865420A1 (en) 2013-09-12
SG10201507865QA (en) 2015-10-29

Similar Documents

Publication Publication Date Title
HRP20160387T1 (hr) Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor
HRP20241590T1 (hr) Supstituirani heterociklički fuzirani ciklički spoj, postupak njegove pripreme i njegova farmaceutska uporaba
HRP20201681T1 (hr) Inhibitor aurora a kinaze
HRP20190831T1 (hr) Mješavina rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
BR112015023705A2 (pt) composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia)
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
JP2015509540A5 (enExample)
HRP20180455T1 (hr) Natrijev (2r, 5s, 13ar) -7, 9-diokso-10- ( (2,4,6-trifluorobenzil) karbamoil) -2, 3, 4, 5, 7, 9, 13, 13a-oktahidro-2, 5-metanopirido [1’,2’ : 4.5]pirazino [2,1-b]oksazepin-8-olat
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
HRP20210681T1 (hr) Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
ME02757B (me) Indoli
ME02019B (me) SPOJ IMIDAZ0[4,5-c]KINOLIN-2-0NA I NJEGOVA UPOTREBA KAO DVOJNOG INHIBITORA PI3 KINAZE I MTOR"
MX2014014106A (es) Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
MX351305B (es) Antagonistas del receptor de mineralocorticoides.
HRP20161522T1 (hr) Derivati 6.7-dialkoksi kinazolina korisni za liječenje poremećaja povezanih s rakom
MX2016002795A (es) Compuestos de triazolona y usos de los mismos.
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
BR112015016184A2 (pt) derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
GB2488788B (en) Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
EA027986B9 (ru) Соединения триазолона и их применение
JP2013540778A5 (enExample)
HRP20200935T1 (hr) Farmaceutski pripravci i njihova upotreba